Nov 9, 2021, 16:08 by

Researchers will discuss how they employed HEPATOPAC® and HEPATOMUNE® cultures in their disease modeling, lead selection, and ADME evaluation programs.

Nov 9, 2021, 16:08 by

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category

Nov 9, 2021, 16:08 by

Nov 9, 2021, 16:08 by

Nov 9, 2021, 16:08 by

CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company has recently launched 3D-QSAR services for scientists to accelerate the drug development process.

Nov 9, 2021, 16:08 by

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has announced it has been shortlisted for three international awards. CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) has been selected as a finalist for the Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award at the Scrip Awards. The company is also in the running for two Citeline Awards: ´Best Sponsor-facing Technology Initiative´ for their business intelligence platform, BEYOND. As well as ´Excellence in Innovation in Response to COVID-19 - Clinical Trial Activities´, for its work with Pfizer / BioNTech.

Nov 9, 2021, 16:08 by

Nov 9, 2021, 16:08 by

Rho, a full-service contract research organization (CRO), is showcasing its clinical development expertise during the 12th Annual CNS Summit, taking place at the Encore Boston Harbor Hotel from November 7-10, 2021. Rho’s Chief Medical Officer, Dr. Jack Modell, along with Dr. John Greist and Dr. Thomas Laughren, will present during a Spotlight Session at the Summit. The 50-minute breakout session, titled, “The Seven Essentials of Clinical Development: How to Avoid Shooting Yourself in the Foot” will showcase the speakers’ combined experience in clinical medicine, academic research, regulatory affairs, and development of drugs and medical applications of information technology.

Nov 9, 2021, 16:08 by

Cardinal Health will explore how to better standardize real world evidence for use in regulatory decisions

Nov 9, 2021, 16:01 by

Ability to meet evolving requirements, including IDMP, ensures regulatory compliance for leading companies

Nov 9, 2021, 16:01 by

Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

Nov 9, 2021, 16:00 by

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Nov 9, 2021, 16:00 by

The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs

Nov 9, 2021, 16:00 by

TARA Biosystems, a biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.

Nov 9, 2021, 16:00 by

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Nov 9, 2021, 16:00 by

eClinical Solutions LLC, a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, announced the inclusion of its Risk-Based Quality Management (RBQM) offering within the elluminate Clinical Data Cloud. With this offering, clinical teams can transform numerous data streams into actionable analytics and statistically significant insights for a holistic, risk-based monitoring approach.

Nov 9, 2021, 16:00 by

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Nov 9, 2021, 16:00 by

230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development

Nov 9, 2021, 16:00 by

Clinical Ink — a global clinical trial data and technology company and leader in eSource and decentralized clinical trial conduct — today announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with an unrivaled modular platform for complex cognitive, behavioral, and physiological data capture.

Nov 9, 2021, 16:00 by

Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base